We are live on ! Find out more
ZVRA icon

Zevra Therapeutics
ZVRA

71 hedge funds and large institutions have $73.1M invested in Zevra Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

195% more call options, than puts

Call options by funds: $19.9M | Put options by funds: $6.77M

50% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 16

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

1% more funds holding

Funds holding: 70 → 71 (+1)

0.36% less ownership

Funds ownership: 22.63% → 22.27% (-0.36%)

25% less capital invested

Capital invested by funds: $98.1M → $73.1M (-$25M)

Holders
71
Holders Change
+1
Holders Change %
+1.43%
% of All Funds
1.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
24
Reduced
16
Closed
12
Calls
$19.9M
Puts
$6.77M
Net Calls
+$13.2M
Net Calls Change
-$3.72M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.87M
2
Goldman Sachs
Goldman Sachs
New York
+$1.7M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.67M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.44M
5
AQR Capital Management
AQR Capital Management
Connecticut
+$1.02M

Top Sellers

1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$9.27M
2
CH
CVI Holdings
Delaware
-$3.13M
3
SM
Sabby Management
Florida
-$1.32M
4
VF
Virtu Financial
New York
-$916K
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$345K
Name Holding Trade Value Shares
Change 		Change in
Stake
HWA
51
Heritage Wealth Advisors
Virginia
$74.6K +$80.6K +8,000 New
SO
52
STRS Ohio
Ohio
$61K – – –
Osaic Holdings
53
Osaic Holdings
Arizona
$42K +$35.7K +3,543 +357%
MLICM
54
Metropolitan Life Insurance Company (MetLife)
New York
$33.6K -$53.3K -5,283 -59%
Citigroup
55
Citigroup
New York
$30K +$19.1K +1,897 +139%
CB
56
CNB Bank
Pennsylvania
$28K – – –
Legal & General Group
57
Legal & General Group
United Kingdom
$25K – – –
NFG
58
Next Financial Group
Texas
$23K – – –
MIM
59
MetLife Investment Management
New Jersey
$22.5K -$92.6K -9,185 -79%
AIP
60
Ameritas Investment Partners
Nebraska
$21K – – –
TRCT
61
Tower Research Capital (TRC)
New York
$21K +$2.97K +295 +15%
IA
62
IFP Advisors
Florida
$12K – – –
TIM
63
Tortoise Investment Management
New York
$11K – – –
SSC
64
Syverson Strege & Co
Iowa
$7K – – –
RG
65
Retirement Group
California
$4K – – –
HI
66
Harbour Investments
Wisconsin
$2K – – –
TWA
67
TCI Wealth Advisors
Arizona
$1K – – –
GKWIM
68
Gerber Kawasaki Wealth & Investment Management
California
$1K +$10 +1 New
CFD
69
Creative Financial Designs
Indiana
$1K +$564 +56 New
Hudson Bay Capital Management
70
Hudson Bay Capital Management
Connecticut
– -$9.27M -723,076 Closed
CH
71
CVI Holdings
Delaware
– -$3.13M -244,274 Closed
VF
72
Virtu Financial
New York
– -$916K -71,435 Closed
SFI
73
Susquehanna Fundamental Investments
Pennsylvania
– -$345K -26,892 Closed
SC
74
Sculptor Capital
New York
– -$176K -13,700 Closed
LPL Financial
75
LPL Financial
California
– -$170K -13,250 Closed
1 2
3
4

ZVRA Hedge Fund Activity: Q3 2021 in Review

71 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2021, worth a combined $73.1M — down 25% from $98.1M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ZVRA positions and 12 closed out — a net gain of 2 holders — while 24 added to existing stakes and 16 trimmed.

The largest buyer was Vanguard Group, adding an estimated $3.87M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $9.27M sold.

  • 71 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2021, up from 70 in Q2 2021.
  • Funds reported $73.1M of Zevra Therapeutics stock for Q3 2021, down 25% quarter-over-quarter.
  • 14 funds opened new Zevra Therapeutics positions in Q3 2021 and 12 closed out, a net change of +2 holders.
  • The largest Zevra Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $3.87M added.
  • The largest Zevra Therapeutics seller in Q3 2021 was Hudson Bay Capital Management, an estimated $9.27M sold.

Based on aggregated 13F filings for Q3 2021.